---
title: "Victall released its first-quarter performance, with a net profit attributable to shareholders of RMB 16.5104 million, turning a loss into a profit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237591626.md"
description: "According to the Zhitong Finance APP, Victall released its first-quarter report for 2025. The company's first-quarter operating revenue was 402 million yuan, a year-on-year increase of 27.19%; the net profit attributable to shareholders of the listed company was 16.5104 million yuan, turning a profit; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 12.5053 million yuan, turning a profit; basic earnings per share were 0.04 yuan/share"
datetime: "2025-04-25T14:05:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237591626.md)
  - [en](https://longbridge.com/en/news/237591626.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237591626.md)
---

# Victall released its first-quarter performance, with a net profit attributable to shareholders of RMB 16.5104 million, turning a loss into a profit

According to the Zhitong Finance APP, Victall (605001.SH) released its first-quarter report for 2025. The company's first-quarter operating revenue was 402 million yuan, a year-on-year increase of 27.19%; the net profit attributable to shareholders of the listed company was 16.5104 million yuan, turning a profit; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 12.5053 million yuan, also turning a profit; basic earnings per share were 0.04 yuan/share

### Related Stocks

- [605001.CN](https://longbridge.com/en/quote/605001.CN.md)

## Related News & Research

- [Orkla (OB:ORK) Margin Improvement Challenges Cautious Earnings Narratives Heading Into Q1 2026](https://longbridge.com/en/news/287134604.md)
- [Obamacare Meltdown? Sharp ACA Enrollment Drop Expected As Pandemic-Era Subsidies End](https://longbridge.com/en/news/287067300.md)
- [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [Assessing BlueNord (OB:BNOR) Valuation After Its US$400 Million Refinancing Deal](https://longbridge.com/en/news/287098111.md)